---
schema_version: "secwatch.filing_event.v1"
accession: "0001493152-26-036256"
form_type: "8-K"
ticker: "HROW"
cik: "0001360214"
company_name: "HARROW, INC."
filed_at: "2026-08-06T11:15:26+00:00"
generated_at: "2026-08-06T11:20:16.193205+00:00"
event_type: "m_and_a"
sentiment: "positive"
materiality_score: 0.75
calibrated_materiality_score: 0.75
confidence: "high"
source: SEC EDGAR
---

# Harrow acquires global rights to TYRVAYA nasal spray for dry eye disease from Viatris for up to $100M

## Summary
- $30M cash at closing plus up to $70M in contingent milestone payments tied to TYRVAYA net sales.
- TYRVAYA is first and only FDA-approved nasal spray for dry eye disease; approved in US, China, Taiwan.
- Complements Harrow's VEVYE franchise with different mechanism (stimulates basal tear production vs anti-inflammatory).
- Expected to close in H2 2026, subject to customary closing conditions.
- Harrow expects to fund upfront cash payment from cash on hand.

## SEC filing metadata
- accession: 0001493152-26-036256
- form_type: 8-K
- ticker: HROW
- cik: 0001360214
- company_name: HARROW, INC.
- filed_at: 2026-08-06T11:15:26+00:00
- event_type: m_and_a
- sentiment: positive
- materiality_score: 0.75
- calibrated_materiality_score: 0.75
- confidence: high
- sec_items: 1.01, 7.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1360214/000149315226036256/0001493152-26-036256-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1360214/000149315226036256/form8-k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001493152-26-036256
- JSON: https://secwatch.observer/filing/0001493152-26-036256.json
- Plain text: https://secwatch.observer/filing/0001493152-26-036256.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.